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Abstract

Small Renal Mass

Evaluation and Management of Small Renal Mass

Definitions and Key Facts
Background:
One of the most common incidental or unexpected findings on
diagnostic imaging scan is a kidney cyst or mass. The incidence
is rising due to increased diagnostic imaging, longer life
expectancy, better quality imaging,
Incidence:
1980s and before, kidney masses weren’t usually found until
they were much larger and symptomatic. Classic triad of flank
pain
an abdominal mass and blood in the urine.
Subtle signs and symptoms like fever, cough, fatigue, weight
loss, edema.

Renal Incidentaloma
•
•
•

Tumor (Solid)
Can be benign or malignant
Benign:

•

Review of Literature:
Since the 1980’s and after, there has been a surge in diagnostic
imaging and likewise the number of renal incidentalomas.
Reasons include longer life expectancy, increased availability of
imaging, and better quality of scans. Most renal masses are
asymptomatic and are found incidentally. 20-30% of small renal
masses are benign or non-cancerous. A

Implications for Practice:
Providers in many different settings ordering areas may benefit
from knowledge of how to triage these patients, how to talk to
patients about these findings, and to know which findings
warrant a referral for further evaluation and management.
Therefore, there is no rush for urgent consult for evaluation and
treatment if <3 to 4 cm.

50% of the time renal masses are found incidentally.
Most incidentalomas are asymptomatic and unrelated to why they
were found.
The vast majority of renal incidentalomas are small renal masses (1 to
4 cm).

The most common benign renal tumors are Oncocytomas and
Angiomyolipomas.

Active Surveillance
Appropriate for most small renal
masses, meaning no rush for urgent
consult or treatment if <3 to 4 cm.
Adv antages Avoids or delays
overtreatment, Ability to perform
future treatment not affected by AS

Disadv antages
Requires close monitoring
Small but possible risk of metastasis

Biopsy
• Percutaneous image-guided by IR
• Fine needle aspiration (FNA) and
multiple cores of tumor
• Indicated if suspect hematologic,
urothelial, metastatic, inflamatory,
or infectious etiology, Competing
medical risks
• Contraindicated (relative) in cystic
or very central renal mass

Useful in pts with solitary kidney, low
kidney function, poor surgical
candidate, tumor recurrence after
surgery

Adv antages
Avoids or delays overtreatment
20-40% of small renal masses are
BENIGN.

Disadv antages
Long term data on cancer control not
available
Slightly higher recurrence rate
Chance of tumor
persistence/recurrence
More imaging compared to after
surgical resection (yearly indefinitely)

Malignant:
•

Renal Cell Carcinoma (RCC) 80-85% of all kidney cancers

•

RCC originates from the outer portion of the kidney called the renal
cortex. Since these cells are so metabolically active, they are the ones
most prone to dysplasia or cancer.

•

RCC is usually asymptomatic unless tumors are quite large or
metastatic.

•

Urothelial Carcinoma 6 to 7%

•

urothelial carcinoma originates from the renal pelvis, ureters or
bladder. It is also called transitional cell carcinoma, which are the type
of cells that line the upper and lower urinary tract. Treatment for
urothelial renal masses is different than RCC since it is more similar to
bladder cancer

•

Other rare types ~5% or metastasis from other primary cancer

Ablation

Disadv antages
• 1-2% complication rate
hemorrhage or infection
• 10% - 15% nondiagnostic rate
Needle is inserted into the tumor
percutaneously and heat or ice
destroys cancer cells.
Radiofrequency ablation creates
heat,
Cryoablation causes freezing.
Indicated for solid renal masses <3 4 cm

Adv antages Minimally invasive
Faster recovery (than surgery)
Preserves renal function (similar to
PN)

What Makes a Renal Mass Suspicious?
Surgery

Can be done open or laparoscopic,
and may be radical nephrectomy or
partial nephrectomy
Type of surgery performed is based
on the size and location of the tumor,
which may vary by surgeon or
facility.
Partial best when possible, because
kidney function is preserved.
However, partial nephrectomy is
more technically challenging
procedure (High-volume center is
best)
Higher risk of complications (than
radical) like bleeding and urine leak
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Benign “bag of fluid”

•

50% of patients age 50

•

Do not affect kidney function, cause symptoms, or turn into cancer

Complex:
•

Most are benign

Bosniak Classification for Cystic Renal Masses

System developed in 1986 by a radiologist to categorize and risk stratify.
Bos
Bos
Bos
Bos

1 and 2 % chance of malignancy
2F has a 5% chance of malignancy
3 has a 50% chance of malignancy
4 has a 90% chance of malignancy

YES! Small renal masses metastasize VERY
RARELY (~1 to 2%). 20-40% of small renal
masses are BENIGN.

Overview of imaging (MRI vs CT)
CT
Preferred for most small renal masses
Enhancement (Hounsfield unit)
Radiation exposure
No contrast if allergic or eGFR <30
Excellent soft tissue discrimination for vessels,
cystic lesions
Caution if claustrophobia or metal implant.

When to Refer to Urology

Simple:
•

Is Active Surveillance Safe?

MRI

Cystic mass (fluid)
References

Solid enhancing mass is suspicious for renal
cell carcinoma.

Triggers for Change from Active
Surveillance to Treatment
Change in tumor
• Increased size >3cm
• Grows 5mm/yr (3mm/yr is average)
• Cystic to solid
• Increased contrast enhancement

Clinical Pearl

>5mm/yr grow th rate or >2cm size.
Bosniak Criteria can guide referral and
management for cystic masses.
Simple cysts do not need follow up or referral.
Refer to Suspicion of Cancer clinic renal
lesions < 2cm.

Take Home Points
“Do a biopsy when you need to, do a partial
nephrectomy (or ablation) when you can, do
a radical nephrectomy when you can’t, and
do active surveillance when the patient
can’t.”

Most renal masses are asymptomatic and are
found incidentally
Simple cysts = ignore
Solid enhancing mass = suspicious

(Karam, 2017)

Patient Anxiety or concern
Patient health improved
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